The British Association of Dermatologists’ Biologic Interventions Register (BADBIR) was set up in 2007. Prof. dr. Christopher Griffiths explains that over the years, the BADBIR has been able to collect data from the safety perspective and effectiveness of the biologic therapies for psoriasis. Most dermatologists will be aware of studies and clinical trials which are required for registration of the drug. But patients who are eligible to go into these trials are not truly representatives of the clients we see in the clinics. Therefore, with BADBIR, we can compare these biological therapies against conventional systemic therapies, and compare the effectiveness and safety.
Meer informatie is alleen toegankelijk voor abonnees die voorschrijfbevoegd zijn.
LoginLet op: Om alle informatie te kunnen zien heeft u een account nodig om in te loggen. Bent u al ingelogd? Dan heeft u onvoldoende rechten om deze informatie te bekijken. Wilt u uw account aanpassen? Klik dan hier
Experts
- Prof. dr. Christopher Griffiths, Professor of Dermatology, University of Manchester | President of the European Society for Dermatological Research
- Tom van ’t Hek, moderator
This podcast is sponsored by
1020COS102647
Recently, the webcast Psoriasis in COVID-19 era: how do we manage psoriasis in 2021? was broadcasted live on MedNet. Click here if you want to watch the webcast on demand. Or listen here to the podcast The ambition in the treatment of psoriasis, where prof. dr. Peter van de Kerkhof and prof. dr. Kristian Reich talk about this subject.